<DOC>
	<DOCNO>NCT01944774</DOCNO>
	<brief_summary>The purpose study Evaluate Efficacy , safety pharmacokinetics Intravenous Nemonoxacin Compared Intravenous Moxifloxacin Adult Patients community-acquired pneumonia ( CAP ) .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety Intravenous Infusion With Nemonoxacin Malate Sodium Chloride</brief_title>
	<detailed_description>Community-acquired Pneumonia ( CAP ) remain leading cause death develop developed country . In choice antibacterial agent use treat CAP , fluoroquinolones receive considerable attention wide spectrum bactericidal activity . TG-873870 ( Nemonoxacin ) , non-fluorinated quinolone ( NFQ ) , selective bacterial topoisomerase inhibitor . This study Evaluate clinical efficacy , microbiological efficacy safety Intravenous Nemonoxacin compare Intravenous Moxifloxacin adult patient community-acquired pneumonia . Besides , pharmacokinetics ( PK ) Nemonoxacin adult patient CAP continuous IV Infusion pharmacokinetic ( PK ) /pharmacodynamic ( PD ) determine .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Ages 18 75 ; 2 . Weighs 40 ~ 100 kg , BMI â‰¥ 18 kg/m2 ; 3 . Must clinical diagnosis CAP 4 . Chest Xray /or CT scan show new persist/progressive infiltrates 5 . Patients PORT/PSI score II , III IV . 6 . If female , nonlactating risk pregnancy ( postmenopausal must use adequate birth control ) 7 . The patient able receive intravenous infusion drug . 1 . Patients PORT/PSI score I VI . 2 . Severe CAP present patient need invasive mechanical ventilation require vasopressor . 3 . Known suspect severe bronchiectasis , cystic fibrosis , active pulmonary tuberculosis infection mycobacteria fungi , know bronchial obstruction , history postobstructive pneumonia , confound respiratory disease , lung cancer , malignancy metastatic lung , lung abscess , empyema , suspect aspiration pneumonia due vomiting , nonbacterial respiratory infection ( chronic obstructive pulmonary disease [ COPD ] exclusionary ) 4 . Clinically significant conduction abnormality 12lead ECG , QTc interval 5 . Potassium &lt; 3.5 mmol/L 6 . Any known disease seriously affect immune system 7 . Active hepatitis decompensated cirrhosis ; 8 . Have use quinolones fluoroquinolones within 14 day enrollment 9 . Patients longterm medication steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Moxifloxacin</keyword>
</DOC>